Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis

Published:2021-10-20 Issue:11-12 Volume:54 Page:1405-1415
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Safadi Rifaat¹,Braun Marius²,Francis Adi³,Milgrom Yael¹,Massarwa Muhammad¹,Hakimian David¹,Hazou Wadi¹,Issachar Assaf²,Harpaz Zivit⁴,Farbstein Motti⁴,Itzhak Inbal⁴,Lev‐Cohain Naama⁵,Bareket‐Samish Avital⁶,Silverman Michael H.⁴,Fishman Pnina⁴^ORCID

Affiliation:

1. The Liver Unit Hadassah Medical Organization Hadassah Hebrew University Medical Centre Jerusalem Israel

2. The Liver Institute Rabin Medical Centre Beilinson Hospital Petah‐Tikva Israel

3. Cardiology Department Holy Family Hospital Nazareth Israel

4. Can‐Fite BioPharma Ltd Petah‐Tikva Israel

5. The Radiology Dep. Hadassah Medical Organization Hadassah Hebrew University Medical Centre Jerusalem Israel

6. BioInsight Ltd Binyamina Israel

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16664

Reference23 articles.

1. A position statement on NAFLD/NASH based on the EASL 2009 special conference

2. Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

3. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

4. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

5. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. 2-Substituted (N)-Methanocarba A₃ Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization;ACS Pharmacology & Translational Science;2024-06-06

3. Adenosine A3 Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases;International Journal of Molecular Sciences;2024-05-25

4. Adaptation of Clinical Practice Guideline for Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in Isfahan Province;International Journal of Preventive Medicine;2024-05

5. Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma;Biomedicines;2024-04-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3